Skip to main content
Bipolar disorder News Noethen
© Rolf Müller / UKB

News categories: Publication

Large study on the genetics of bipolar disorder

Genetic factors play a major role in the development of bipolar disorder. In an effort to better understand the underlying biology, researchers are constantly studying the genetic makeup of people with bipolar disorder. The Psychiatric Genomics Consortium's Genome-Wide Association Study (GWAS) is the largest of its kind. The study analyzes data from ver 150,000 people of European, East Asian, African-American and Latin American descent. The latest results have now been published in the renowned scientific journal “Nature”.

Either manic episodes with lots of energy or the complete opposite: depression and listlessness - this is what the days of people with bipolar disorder can look like. An estimated 40 to 50 million people worldwide are affected. The illness is associated with a number of negative consequences and risks, including an increased risk of suicide. The causes of bipolar disorder are complex and the biology on which it is based is still largely unexplored. What is clear, however, is that a key risk factor for bipolar disorder is a genetic predisposition. Small variants in a large number of genes are responsible for this predisposition.

“The more we know about the biology behind the disorder and the risk factors, the greater the chance of improved diagnosis and treatment options through precision medicine,” explains Prof. Dr. Andreas Forstner from the Institute of Human Genetics at the UKB and shared last author of the study. He is a member of the Transdisciplinary Research Area (TRA) “Life and Health” at the University of Bonn and also works at the Institute of Neuroscience and Medicine (INM-1) at Forschungszentrum Jülich.

The study compared the genes of more than 2.9 million participants, including over 150,000 people with bipolar disorder. The idea behind this is that many people with bipolar disorder have the same genetic variants that are partly responsible for the illness.

New responsible genes discovered

In total, the study identified 298 regions of the genome in which genetic variants increase the risk of bipolar disorder - 267 of which were newly discovered in the current version of GWAS. The study also identified a new region that is associated with an increased risk of bipolar disorder, particularly in samples of East Asian origin. In the identified regions, 36 specific genes are suspected to be relevant for bipolar disorder. The next steps in research could be to investigate these genes in more detail. They could also be used to research new targets for drugs against bipolar disorder.

“In the study, we also found genetic differences between different clinical manifestations of bipolar disorder. This may be important for research into new diagnostic and treatment approaches,” says Prof. Dr. Markus Nöthen, Director of the Institute of Human Genetics at the UKB and co-author of the study. He is a member of the Cluster of Excellence ImmunoSensation2 of the Transdisciplinary Research Area (TRA) “Life and Health” and at the University of Bonn.

“Our results also suggest that different types of nerve cells in the brain play a role in bipolar disorder, and possibly also certain cells outside the brain. This is where further research can start,” adds Friederike David, doctoral student at the University of Bonn's Institute of Human Genetics at the UKB and shared second author of the study.

Funding

The study was conducted by the Psychiatric Genomics Consortium (PGC), an international consortium of researchers investigating the genetics of mental illness. The PGC comprises over 800 researchers from more than 150 institutions in over 40 countries. In German-speaking countries, in addition to the UKB and the University of Bonn, the Central Institute of Mental Health in Mannheim, the University Hospital of Munich, the Department of Psychiatry and Psychotherapy at the University Hospital of Marburg, the Department of Mental Health at the University Hospital of Münster and the University Hospital of Basel were also involved.

The study was funded by the US National Institute of Mental Health, among others.

Publikation

Kevin S. O’Connell et al.: Genomics yields biological and phenotypic insights into bipolar disorder; Nature; DOI: https://doi.org/10.1038/s41586-024-08468-9

 

Contact

Prof. Dr. Markus M. Nöthen

Director of the Institut of Human Genetics

University Hospital Bonn

Phone +49 228 287-51100

E-mail: markus.noethen@uni-bonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview